// App-Quantinova.ai

7548.0 : Discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia in chronic phase (CML-CP) in US clinical practice after guideline updates.

Researchers

Presenter

  • Ehab L. Atallah

Principal Investigators

  • Islam Sadek

  • Rodrigo O. Maegawa

  • Xiting Cao

  • Dominick Latremouille-Viau

  • Irina Pivneva

  • Carmine Rossi

  • Annie Guerin

  • Vamsi Kota

Medical Centers

  • Hematologic Malignancies, Medical College of Wisconsin, Milwaukee, WI

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Analysis Group, Inc., Montreal, QC, Canada

  • Georgia Cancer Center, Augusta University, Augusta, GA

Locations

  • United States

  • Canada

Companies

  • Novartis AG

  • Analysis Group, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved